LASIK Eye Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

LASIK (Laser-Assisted In Situ Keratomileusis) is the world's most commonly performed elective surgical procedure — approximately 10 million LASIK procedures are performed annually globally — and permanently corrects refractive errors (myopia, hyperopia, and astigmatism) by reshaping the cornea to alter the eye's focusing power. The procedure involves two laser steps: a femtosecond laser (IntraLase, VisuMax, FEMTO LDV) creates a thin corneal flap (90–110 microns) which is lifted to expose the stroma; then an excimer laser (ArF 193 nm — Alcon WaveLight EX500, J&J iDesign, Zeiss MEL 90) ablates stromal tissue in a precise computer-guided pattern to reshape the corneal surface and correct the refractive error; the flap is then repositioned and adheres without sutures. The entire laser treatment takes 15–30 seconds per eye; the complete procedure including preparation, flap creation, and ablation takes approximately 15 minutes per eye. LASIK corrects: myopia up to -12D (optimal range -1 to -8D), hyperopia up to +4D (optimal range +1 to +3D), and astigmatism up to 6D in combination with sphere. Modern LASIK uses wavefront-guided or wavefront-optimized ablation profiles, custom-designed to each patient's corneal topography and higher-order aberration pattern, achieving optical quality superior to spectacles. SMILE (Small Incision Lenticule Extraction — Zeiss VisuMax) is a flapless alternative for myopia correction, extracting a lenticule through a 3 mm opening, with early evidence of reduced dry eye and flap-related complications.

Myopia (nearsightedness — most prevalent refractive error globally, affecting 2.6 billion people): LASIK flattens the cornea by removing central stroma, reducing focusing power to shift the focal point from in front of to on the retina. Optimal range -1 to -8D; up to -12D possible if sufficient corneal thickness. Hyperopia (farsightedness — difficulty with near vision): LASIK steepens the central cornea by removing peripheral stroma; effective for +1 to +3D; regression more common than myopia correction; +4 to +6D can be treated with less predictable outcomes. Astigmatism (irregular corneal curvature causing blurred vision at all distances): excimer laser ablates different amounts of stroma in different meridians to normalize curvature; treated in combination with sphere. Presbyopia (age-related loss of near focus — not a refractive error but accommodation failure): monovision LASIK (correcting dominant eye for distance, non-dominant for near) is the primary surgical approach — achieving functional near and distance vision without glasses in 85–90% of appropriately motivated patients who adapt to monovision. Presbyopia-specific LASIK (PresbyLASIK — multifocal corneal ablation profile) is available at select centers with good results (70–80% spectacle independence). Residual refractive error after LASIK (undercorrection or regression): LASIK enhancement (flap re-lift + re-ablation) can be performed if corneal thickness is sufficient, typically 3–12 months post-primary procedure.

LASIK candidacy assessment is the most critical step — inappropriate patient selection is responsible for most poor outcomes. Eligibility criteria: Age ≥18 years (22+ preferred — refraction should be stable for 1+ year); stable refraction for ≥12 months (no prescription change >0.5D in 12 months); adequate corneal thickness (minimum 500 microns total; residual stromal bed after ablation ≥250–300 microns to prevent ectasia); normal corneal topography — no keratoconus, forme fruste keratoconus, or irregular astigmatism (Scheimpflug topography/tomography with posterior float mapping is mandatory — screening out subclinical keratoconus is essential as LASIK on keratoconic corneas causes progressive ectasia); adequate pupil size assessment; dry eye evaluation (DEWS II criteria — moderate-severe dry eye is a relative contraindication requiring treatment before LASIK); myopia correction within safe ablation depth. Absolute contraindications: keratoconus or forme fruste keratoconus (LASIK is contraindicated — corneal crosslinking or ICL is preferred); thin cornea (<500 microns); autoimmune disease affecting healing (lupus, rheumatoid arthritis — relative); active ocular disease (infection, uveitis); pregnancy/breastfeeding (refraction unstable); HIV (poor healing); herpes simplex keratitis in the treated eye; severe dry eye disease. Alternatives for ineligible patients: SMILE (flapless — better for thin corneas and contact sports); PRK/LASEK (surface ablation — no flap, longer recovery, better for thin corneas); phakic ICL (implantable collamer lens — EVO-ICL for high myopia unsuitable for laser correction, preserves corneal tissue completely); lens-based surgery (refractive lens exchange for presbyopia with multifocal IOL).

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

LASIK achieves extraordinary visual outcomes in properly selected patients. A comprehensive meta-analysis (Sandoval et al. 2016 — 4,400 peer-reviewed studies): 99.5% of patients achieve UCVA ≥20/40 (legally corrected vision for driving without glasses); 90.8% achieve UCVA ≥20/20; 89.7% achieve within ±0.5D of intended correction. Patient satisfaction surveys consistently report 95–96% satisfaction rate — among the highest of any elective procedure. Freedom from glasses and contact lenses: 95%+ spectacle independence for distance after myopia LASIK. Visual quality: wavefront-guided LASIK may deliver supranormal contrast sensitivity and resolution, exceeding spectacle-corrected quality. Lifestyle benefits: freedom for sports, swimming, travel, military/aviation careers (subject to service-specific regulations), and improved self-esteem. Long-term stability: myopia LASIK outcomes are stable for 10+ years in the vast majority; minor regression (~0.5D over 10 years in high myopes) may be corrected with enhancement. Hyperopia and astigmatism LASIK outcomes are slightly less stable at high corrections. Economic benefit: lifetime savings on spectacles, contact lenses, and maintenance are significant, often exceeding LASIK cost over 10–15 years. FDA patient-reported outcomes (PROWL study): 95.3% of patients satisfied; vision-related quality of life improved significantly in all validated questionnaire domains.

LASIK is generally very safe with a low serious complication rate at experienced centers with proper patient selection. Dry eye (the most common side effect): transient dry eye symptoms affect 20–40% for 3–6 months post-LASIK (flap creation cuts corneal nerves causing reduced sensation and decreased basal tear production); severe or prolonged dry eye in 1–5%. Pre-existing dry eye dramatically worsens post-LASIK. Prevention: thorough pre-operative dry eye treatment; use of artificial tears; punctal plugs if needed; omega-3 supplementation. Halos and glare around lights at night: most common in the first 3 months; persistent troublesome dysphotopsia in 5–10%; higher risk in large pupil sizes and high myopia corrections. Wavefront-guided ablation profiles reduce higher-order aberration and dysphotopsia versus older treatments. Corneal ectasia (progressive corneal weakening/steepening after LASIK): the most feared serious complication — occurs in 0.04–0.6% of cases; risk dramatically reduced by rigorous pre-operative screening (excluding subclinical keratoconus); managed with corneal crosslinking to halt progression; may progress to need corneal transplant. Undercorrection/overcorrection: 5–10% undercorrection; 1–3% overcorrection; most correctable with enhancement procedure. Flap complications: flap displacement (rare — <0.1%); epithelial ingrowth under flap (2–3% with re-lifts, 0.2% primary LASIK); flap striae (wrinkles from trauma — requires immediate flap relift). Infection (diffuse lamellar keratitis — 'sands of the Sahara'): inflammatory response under flap from endotoxins — 1–3% mild cases; 0.01% severe vision-threatening. Regression: myopic regression of 0.5–1D over 10 years in high myopes — management by enhancement if corneal thickness allows.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

LASIK is a leading medical tourism procedure with India being the global leader for cost-quality value. In the USA, standard LASIK (bilateral both eyes): $2,000–$3,000 per eye or $4,000–$6,000 bilateral (standard); $4,000–$6,000 per eye for wavefront-guided/custom LASIK; $5,000–$8,000 per eye for SMILE. Total bilateral USA LASIK with premium technology: $8,000–$15,000. UK: £1,500–£3,000 per eye standard; £2,500–£4,500 wavefront. In India, LASIK at renowned eye centers (Shroff Eye Centre, Centre for Sight, Maxivision, L.V. Prasad, Sharp Sight, Vasan Eye Care): standard LASIK ₹25,000–₹50,000 bilateral ($300–$600 bilateral); wavefront-guided LASIK ₹40,000–₹90,000 bilateral ($480–$1,080); SMILE ₹70,000–₹1,50,000 bilateral ($840–$1,800). All bilateral, both eyes. Representing 80–95% savings versus US prices. The technology used (Alcon WaveLight EX500, Zeiss MEL 90, Schwind Amaris) is identical to US and European centers. Thailand: LASIK bilateral $1,800–$3,500; SMILE $2,500–$4,500. Turkey: LASIK $1,500–$3,000; SMILE $2,000–$4,000. Mexico: $1,500–$3,000. Singapore: $2,000–$4,000 per eye. Pre-LASIK evaluation (corneal topography, pachymetry, aberrometry): ₹2,000–₹6,000 ($24–$72) in India. LASIK medical tourism typically involves 3–5 day stay: evaluation day 1, procedure day 2, post-operative check day 3, discharge with drops and follow-up instructions.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.